Proteopathic tau seeding predicts tauopathy in vivo

Significance Prion-like propagation of proteopathic seeds may underlie the progression of neurodegenerative diseases, including the tauopathies and synucleinopathies. We aimed to construct a versatile and simple cell assay to sensitively and specifically detect proteopathic seeding activity. Using a combination of FRET flow cytometry and a tau monoclonal FRET biosensor cell line, we report seed detection in the femtomolar range. This assay is easily applied to human brain homogenates and selectively responds to Alzheimer's disease but not Huntington's disease brains. By comparing seeding activity in a mouse model of human tauopathy, we demonstrate detection of proteopathic seeding far in advance of standard histopathological markers. Proteopathic seeding is thus an early marker of tauopathy, consistent with a causal role for tau seeds in neurodegeneration. Transcellular propagation of protein aggregates, or proteopathic seeds, may drive the progression of neurodegenerative diseases in a prion-like manner. In tauopathies such as Alzheimer’s disease, this model predicts that tau seeds propagate pathology through the brain via cell–cell transfer in neural networks. The critical role of tau seeding activity is untested, however. It is unknown whether seeding anticipates and correlates with subsequent development of pathology as predicted for a causal agent. One major limitation has been the lack of a robust assay to measure proteopathic seeding activity in biological specimens. We engineered an ultrasensitive, specific, and facile FRET-based flow cytometry biosensor assay based on expression of tau or synuclein fusions to CFP and YFP, and confirmed its sensitivity and specificity to tau (∼300 fM) and synuclein (∼300 pM) fibrils. This assay readily discriminates Alzheimer’s disease vs. Huntington's disease and aged control brains. We then carried out a detailed time-course study in P301S tauopathy mice, comparing seeding activity versus histological markers of tau pathology, including MC1, AT8, PG5, and Thioflavin S. We detected robust seeding activity at 1.5 mo, >1 mo before the earliest histopathological stain. Proteopathic tau seeding is thus an early and robust marker of tauopathy, suggesting a proximal role for tau seeds in neurodegeneration.

[1]  Alexxai V. Kravitz,et al.  Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. , 2004, Experimental neurology.

[2]  J. Trojanowski,et al.  Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.

[3]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[4]  J. Ávila,et al.  Characteristics of the binding of thioflavin S to tau paired helical filaments. , 2006, Journal of Alzheimer's disease : JAD.

[5]  Sangmook Lee,et al.  Interneuronal transfer of human tau between Lamprey central neurons in situ. , 2010, Journal of Alzheimer's disease : JAD.

[6]  B. Caughey,et al.  Prion Seeding Activities of Mouse Scrapie Strains with Divergent PrPSc Protease Sensitivities and Amyloid Plaque Content Using RT-QuIC and eQuIC , 2012, PloS one.

[7]  S. Prusiner,et al.  Shattuck lecture--neurodegenerative diseases and prions. , 2001, The New England journal of medicine.

[8]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[9]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[10]  S. Prusiner,et al.  Some speculations about prions, amyloid, and Alzheimer's disease. , 1984, The New England journal of medicine.

[11]  J. Trojanowski,et al.  P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating , 2011, PloS one.

[12]  P. Davies,et al.  Conformational change as one of the earliest alterations of tau in Alzheimer’s disease , 2000, Neurobiology of Aging.

[13]  J. Winderickx,et al.  Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies , 2014, Acta neuropathologica communications.

[14]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[15]  E. Vanmechelen,et al.  Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205 , 1995, Neuroscience Letters.

[16]  D. Holtzman,et al.  Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* , 2012, The Journal of Biological Chemistry.

[17]  D. Holtzman,et al.  In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice , 2011, The Journal of Neuroscience.

[18]  Bin Zhang,et al.  Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.

[19]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[20]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[21]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[22]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[23]  C. Zurzolo,et al.  Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons* , 2012, The Journal of Biological Chemistry.

[24]  Alexxai V. Kravitz,et al.  Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation , 2004, Experimental Neurology.

[25]  V. Lee,et al.  Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles* , 2011, The Journal of Biological Chemistry.

[26]  Clemens F. Kaminski,et al.  Extracellular Monomeric Tau Protein Is Sufficient to Initiate the Spread of Tau Protein Pathology* , 2013, The Journal of Biological Chemistry.

[27]  David W. Colby,et al.  Prion detection by an amyloid seeding assay , 2007, Proceedings of the National Academy of Sciences.

[28]  G. Jicha,et al.  cAMP-Dependent Protein Kinase Phosphorylations on Tau in Alzheimer’s Disease , 1999, The Journal of Neuroscience.

[29]  David W. Colby,et al.  Protein Misfolding Detected Early in Pathogenesis of Transgenic Mouse Model of Huntington Disease Using Amyloid Seeding Assay* , 2011, The Journal of Biological Chemistry.

[30]  V. Haroutunian,et al.  Tau protein abnormalities associated with the progression of alzheimer disease type dementia , 2007, Neurobiology of Aging.

[31]  L. Grinberg,et al.  Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.

[32]  F. Brodsky,et al.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds , 2013, Proceedings of the National Academy of Sciences.

[33]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[34]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[35]  John Collinge,et al.  A General Model of Prion Strains and Their Pathogenicity , 2007, Science.

[36]  A. Klug,et al.  Structural characterization of the core of the paired helical filament of Alzheimer disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Diamond,et al.  Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target* , 2014, The Journal of Biological Chemistry.

[38]  J. Trojanowski,et al.  Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.

[39]  F. Ono,et al.  Ultrasensitive detection of PrP(Sc) in the cerebrospinal fluid and blood of macaques infected with bovine spongiform encephalopathy prion. , 2014, The Journal of general virology.

[40]  D. Holtzman,et al.  Neuronal activity regulates extracellular tau in vivo , 2014, The Journal of experimental medicine.

[41]  E. Cohen,et al.  A kinetic aggregation assay allowing selective and sensitive amyloid-β quantification in cells and tissues. , 2011, Biochemistry.

[42]  M. Weiner,et al.  A Network Diffusion Model of Disease Progression in Dementia , 2012, Neuron.

[43]  Leslie Michels Thompson,et al.  A Rapid Cellular FRET Assay of Polyglutamine Aggregation Identifies a Novel Inhibitor , 2003, Neuron.

[44]  B. Ghetti,et al.  Brain homogenates from human tauopathies induce tau inclusions in mouse brain , 2013, Proceedings of the National Academy of Sciences.

[45]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[46]  David W. Colby,et al.  Conformational features of tau fibrils from Alzheimer's disease brain are faithfully propagated by unmodified recombinant protein. , 2013, Biochemistry.

[47]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[48]  E. Mandelkow,et al.  The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.

[49]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[50]  B. Miller,et al.  Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.

[51]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[52]  Efstathios D. Gennatas,et al.  Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome , 2012, Neuron.

[53]  S. Reske,et al.  FTDP‐17: An early‐onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation , 1999, Annals of neurology.

[54]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[55]  J. Hauber,et al.  A Flow Cytometry-Based FRET Assay to Identify and Analyse Protein-Protein Interactions in Living Cells , 2010, PloS one.

[56]  Menno P. Witter,et al.  Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.

[57]  E. Morignat,et al.  Prion-like acceleration of a synucleinopathy in a transgenic mouse model , 2012, Neurobiology of Aging.

[58]  M. Diamond,et al.  Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.

[59]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[60]  E. Scarpini,et al.  Detection of misfolded Aβ oligomers for sensitive biochemical diagnosis of Alzheimer's disease. , 2014, Cell reports.